These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 11087360)

  • 1. Interaction of the antitumor compound cryptophycin-52 with tubulin.
    Panda D; Ananthnarayan V; Larson G; Shih C; Jordan MA; Wilson L
    Biochemistry; 2000 Nov; 39(46):14121-7. PubMed ID: 11087360
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cryptophycin 1 binds to tubulin at a site distinct from the colchicine binding site and at a site that may overlap the vinca binding site.
    Mooberry SL; Taoka CR; Busquets L
    Cancer Lett; 1996 Oct; 107(1):53-7. PubMed ID: 8913266
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Conformational changes in tubulin upon binding cryptophycin-52 reveal its mechanism of action.
    Eren E; Watts NR; Sackett DL; Wingfield PT
    J Biol Chem; 2021 Oct; 297(4):101138. PubMed ID: 34461087
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mechanism of action cryptophycin. Interaction with the Vinca alkaloid domain of tubulin.
    Smith CD; Zhang X
    J Biol Chem; 1996 Mar; 271(11):6192-8. PubMed ID: 8626409
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antiproliferative mechanism of action of cryptophycin-52: kinetic stabilization of microtubule dynamics by high-affinity binding to microtubule ends.
    Panda D; DeLuca K; Williams D; Jordan MA; Wilson L
    Proc Natl Acad Sci U S A; 1998 Aug; 95(16):9313-8. PubMed ID: 9689077
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interaction of cryptophycin 1 with tubulin and microtubules.
    Kerksiek K; Mejillano MR; Schwartz RE; Georg GI; Himes RH
    FEBS Lett; 1995 Dec; 377(1):59-61. PubMed ID: 8543019
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro effect of cryptophycin 52 on microtubule assembly and tubulin: molecular modeling of the mechanism of action of a new antimitotic drug.
    Barbier P; Gregoire C; Devred F; Sarrazin M; Peyrot V
    Biochemistry; 2001 Nov; 40(45):13510-9. PubMed ID: 11695898
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interactions of the sponge-derived antimitotic tripeptide hemiasterlin with tubulin: comparison with dolastatin 10 and cryptophycin 1.
    Bai R; Durso NA; Sackett DL; Hamel E
    Biochemistry; 1999 Oct; 38(43):14302-10. PubMed ID: 10572005
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Localization of the antimitotic peptide and depsipeptide binding site on beta-tubulin.
    Mitra A; Sept D
    Biochemistry; 2004 Nov; 43(44):13955-62. PubMed ID: 15518544
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro pharmacology of cryptophycin 52 (LY355703) in human tumor cell lines.
    Wagner MM; Paul DC; Shih C; Jordan MA; Wilson L; Williams DC
    Cancer Chemother Pharmacol; 1999; 43(2):115-25. PubMed ID: 9923816
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mechanism of action of the unusually potent microtubule inhibitor cryptophycin 1.
    Panda D; Himes RH; Moore RE; Wilson L; Jordan MA
    Biochemistry; 1997 Oct; 36(42):12948-53. PubMed ID: 9335554
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Binding of the epoxide cryptophycin analog, LY355703 to albumin and its effect on in vitro antiproliferative activity.
    Schultz RM; Shih C; Wood PG; Harrison SD; Ehlhardt WJ
    Oncol Rep; 1998; 5(5):1089-94. PubMed ID: 9683814
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Caulerpenyne binding to tubulin: structural modifications by a non conventional pharmacological agent.
    Bourdron J; Barbier P; Allegro D; Villard C; Lafitte D; Commeiras L; Parrain JL; Peyrot V
    Med Chem; 2009 Mar; 5(2):182-90. PubMed ID: 19275717
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The spongistatins, potently cytotoxic inhibitors of tubulin polymerization, bind in a distinct region of the vinca domain.
    Bai R; Taylor GF; Cichacz ZA; Herald CL; Kepler JA; Pettit GR; Hamel E
    Biochemistry; 1995 Aug; 34(30):9714-21. PubMed ID: 7626642
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Binding of dolastatin 10 to tubulin at a distinct site for peptide antimitotic agents near the exchangeable nucleotide and vinca alkaloid sites.
    Bai RL; Pettit GR; Hamel E
    J Biol Chem; 1990 Oct; 265(28):17141-9. PubMed ID: 2211617
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dolastatin 15 binds in the vinca domain of tubulin as demonstrated by Hummel-Dreyer chromatography.
    Cruz-Monserrate Z; Mullaney JT; Harran PG; Pettit GR; Hamel E
    Eur J Biochem; 2003 Sep; 270(18):3822-8. PubMed ID: 12950266
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterization of the interaction of TZT-1027, a potent antitumor agent, with tubulin.
    Natsume T; Watanabe J; Tamaoki S; Fujio N; Miyasaka K; Kobayashi M
    Jpn J Cancer Res; 2000 Jul; 91(7):737-47. PubMed ID: 10920282
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The thermodynamics of vinca alkaloid-induced tubulin spirals formation.
    Lobert S; Ingram JW; Correia JJ
    Biophys Chem; 2007 Mar; 126(1-3):50-8. PubMed ID: 16757093
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interaction of tubulin with a new fluorescent analogue of vinblastine.
    Chatterjee SK; Laffray J; Patel P; Ravindra R; Qin Y; Kuehne ME; Bane SL
    Biochemistry; 2002 Nov; 41(47):14010-8. PubMed ID: 12437358
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Protein-binding patterns of the antitumor antibiotic cryptophycin 52 as measured with a two-phase partitioning system.
    Kessel D
    J Chromatogr B Biomed Sci Appl; 1999 Nov; 735(1):121-6. PubMed ID: 10630897
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.